News

May 3, 2017May 3, 2017

Three Lakes Partners and MATTER Announce $1M IPF Catalyst Challenge

Three Lakes Partners and MATTER announced a $1 million IPF Catalyst Challenge to engage innovators, entrepreneurs and researchers to find solutions for idiopathic pulmonary fibrosis (IPF) patients’ greatest need – ... Read more

May 2, 2017May 2, 2017

Bellerophon’s INOpulse Shows Promising Results in Patients with PH-IPF Lung Disease

Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

Inhaled nitric oxide (iNO) treatment with the investigational medical device INOpulse system in patients with pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF) has shown promising results in a Phase 2 clinical ... Read more

April 28, 2017April 28, 2017

Phase 1 Interim Trial Results of miRagen’s Anti-Fibrotic Therapy Show Potential

Idiopathic Pulmonary Fibrosis, News

Initial results from a Phase 1 study on miRagen Therapeutics‘ investigative drug MRG-201 on healthy volunteers show potential for fibrous scar tissue in certain diseases. The company announced it will present ... Read more

April 27, 2017April 27, 2017

Experimental Drug RCM-1 May Have Therapeutic Potential to Block Inflammation and Mucus-Producing Cells Expansion

Asthma, News

Researchers from Cincinnati Children’s Hospital Medical Center found a new compound with therapeutic potential to block a protein called FOXM1, which is responsible for pro-inflammatory and hyper-mucous activity in asthma ... Read more

April 26, 2017April 26, 2017

Registration Under Way for Pulmonary Fibrosis Foundation Summit

Idiopathic Pulmonary Fibrosis, News

Registration is under way for this fall’s Pulmonary Fibrosis Foundation Summit in Nashville, a key focus of which will be new research on the disease. Those interested in presenting their studies ... Read more

April 24, 2017April 24, 2017

British Researchers Develop One-Hour Flu and Viral Infections Test

Asthma, COPD, News

British researchers have developed an innovative approach to using a swab test to diagnose flu and other viral infections in patients with respiratory conditions, resulting in shorter courses of antibiotics ... Read more

April 21, 2017April 21, 2017

Heartburn Therapy May Not Be Effective or Safe for IPF Patients on Esbriet

Idiopathic Pulmonary Fibrosis, News

Heartburn treatments, such as antacid therapy (AAT), may not be effective or safe as an add-on treatment for idiopathic pulmonary fibrosis (IPF) patients receiving Esbriet (pirfenidone), according to a study. ... Read more

April 20, 2017April 20, 2017

Boehringer Ingelheim Phase 3 Trial Evaluates Ofev in Patients with Progressive Fibrosing Interstitial Lung Disease

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim Pharmaceuticals has enrolled the first patient in its progressive fibrosing interstitial lung disease (PF-ILD) clinical trial, which will investigate the effectiveness and safety of Ofev (nintedanib) in a ... Read more

April 19, 2017April 19, 2017

FDA Agrees with ProMetic’s Protocol for PBI-4050 in IPF Clinical Trials

Idiopathic Pulmonary Fibrosis, News

ProMetic Life Sciences recently announced that the U.S. Food and Drug Administration (FDA) agreed with the design of the first Phase 2/3 clinical trials evaluating PBI-4050 for idiopathic pulmonary fibrosis (IPF) ... Read more

April 18, 2017April 19, 2017

Bristol-Myers, Nordic Partnering on Development of Biomarkers for Fibrotic Diseases

Idiopathic Pulmonary Fibrosis, News

Bristol-Myers Squibb and Nordic Bioscience have agreed to work together to develop biomarkers for diagnosing and monitoring patients with fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF). IPF is a fatal, rare lung ... Read more